Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients

British Journal of Cancer

Volumn 99, Issue 8, 2008, Pages 1239-1245

  Rouits, E ^a   Charasson, V ^b   Petain A ^c   Boisdron Celle, M ^a   Delord, J P ^c   Fonck, M ^b   Laurand, A ^b   Poirier, A L ^a   Morel, A ^a   Chatelut, E ^c   Robert, J ^b   Gamelin, E ^a  

^a CENTRE PAUL PAPIN   (France)

^b INSTITUT BERGONIÉ   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Colorectal cancer; CYP3A4; Irinotecan; Pharmacokinetics; UGT1A1 gene polymorphism

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; APC; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; TATA BINDING PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; GENETIC VARIABILITY; GLUCURONIDATION; HEREDITY; HUMAN; MALE; METASTASIS; PHARMACOGENETICS; PRIORITY JOURNAL;

EID: 53849098896     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604673     Document Type: Article

References (37)

1. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13: 210-221
2. André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V, de Gramont A (1999) CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur J Cancer 35: 1343-1347
3. Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A (2004) Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 10: 8341-8350
4. Bentrem DJ, Dematteo RP, Blumgart LH (2005) Surgical therapy for metastatic disease to the liver. Annu Rev Med 56: 139-156
5. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481-488
6. Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Hérait P, Lokiec F, Mathieu-Boué A (1996) Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 14: 2688-2695
7. Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boue A, Mahjoubi M, Clavel M (1995) Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 6: 133-140
8. Cecchin E, Corona G, Masier S, Biason P, Cattarossi G, Frustaci S, Buonadonna A, Colussi A, Toffoli G (2005) Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin Cancer Res 11: 6901-6907
9. Charasson V, Bellott R, Meynard D, Longy M, Gorry P, Robert J (2004) Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 76: 528-535
10. Côté JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, Thirouard AS, Selves J, Laurent-Puig P, Ychou M (2007) UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13: 3269-3275
11. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345
12. de Forni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A, Madelaine I, Marty ME, Mathieu-Boué A (1994) Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54: 4347-4354
13. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
14. Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, Leu K, Hollenberg PF, Baker LH (2003) Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol 21: 2481-2485
15. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047
16. Haaz MC, Riché C, Rivory LP, Robert J (1998a) Biosynthesis of an aminopiperidino metabolite of irinotecan (7-ethyl-10-(4-(1-piperidino)-1- piperidino)carbonyloxycamptothecine) by human hepatic microsomes. Drug Metab Dispos 26: 769-774
17. Haaz MC, Rivory L, Riché C, Vernillet L, Robert J (1998b) Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 58: 468-472
18. Herben VM, Schellens JH, Swart M, Gruia G, Vernillet L, Beijnen JH, ten Bokkel Huinink WW (1999) Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J Clin Oncol 17: 1897-1905
19. Hill C, Doyon F (2005) The frequency of cancer in France in year 2000, and trends since 1950. Bull Cancer 92: 7-11
20. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2: 43-47
21. Labianca R, Pessi MA, Zamparelli G (1997) Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy. Drugs 53: 593-607
22. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54: 1271-1294
23. Ma MK, Zamboni WC, Radomski KM, Furman WL, Santana VM, Houghton PJ, Hanna SK, Smith AK, Stewart CF (2000) Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin Cancer Res 6: 813-819
24. Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A (2004) Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96: 1585-1592
25. Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL (2003) Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9: 3246-3253
26. Moses MA, Harper J, Fernandez CA (2004) A role for antiangiogenic therapy in breast cancer. Curr Oncol Rep 6: 42-48
27. Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ, Gobburu JV (2007) The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 47: 78-86
28. Rivory LP, Haaz MC, Canal P, Lokiec F, Armand JP, Robert J (1997) Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 3: 1261-1266
29. Rivory LP, Robert J (1994) A reverse-phase HPLC method for the simultaneous quantification of the carboxylate and lactone forms of the camptothecin derivative irinotecan (CPT-11) and of its metabolite SN-38 in plasma. J Chromatogr B 661: 133-141
30. Rivory LP, Robert J (1995) Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Pharmacol Ther 68: 269-296
31. Rothenberg ML, Eckardt JR, Kuhn JG, Burris III HA, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128-1135
32. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E (2004) Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10: 5151-5159
33. Rouits E, Boisdron-Celle M, Morel A, Gamelin E (2003) Simple and sensitive high-performance liquid chromatography method for simultaneous determination of urinary free cortisol and 6β-hydroxycortisol in routine practice for CYP 3A4 activity evaluation in basal conditions and after grapefruit juice intake. J Chromatogr B 793: 357-366
34. Sasaki Y, Hakusui H, Mizuno S, Morita M, Miya T, Eguchi K, Shinkai T, Tamura T, Ohe Y, Saijo N (1995) A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 86: 101-110
35. Taieb J, Artru P, Paye F, Louvet C, Perez N, Andre T, Gayet B, Hebbar M, Goebel FM, Tournigand C, Parc R, de Gramont A (2005) Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol 23: 502-509
36. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, Pasetto LM, Pessa S, Errante D, De Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E, Bonura S, Boccalon M, Biason P, Frustaci S (2006) The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24: 3061-3068
37. Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N (2000) Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 18: 2301-2308